NCT02185794 is a Phase 1 clinical trial of Voxilaprevir in Hepatitis C Virus Infection, sponsored by Gilead Sciences.

Who is sponsoring NCT02185794?

NCT02185794 is sponsored by Gilead Sciences.

What drugs are being tested in NCT02185794?

Interventions in NCT02185794: Voxilaprevir, Placebo to match voxilaprevir, SOF/VEL.

What condition does NCT02185794 study?

NCT02185794 studies Hepatitis C Virus Infection.

Is NCT02185794 still recruiting?

NCT02185794 is currently completed. Last updated 17 September 2020.

Are results published for NCT02185794?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2020-09-17 · How we verify

NCT02185794

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of Voxilaprevir in Adults With Chronic Hepatitis C Virus Infection

Completed Phase 1 Results posted Last updated 17 September 2020

What this trial tests

Phase 1 trial testing Voxilaprevir in Hepatitis C Virus Infection in 101 participants. Completed in 28 September 2015.

Timeline

13 June 2014

Primary endpoint
22 December 2014

28 September 2015

Quick facts

Lead sponsor	Gilead Sciences
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	treatment
Enrollment	101
Start date	13 June 2014
Primary completion	22 December 2014
Estimated completion	28 September 2015
Sites	11 locations across Puerto Rico, United States

Drugs / interventions tested

Voxilaprevir — full drug profile →
Placebo to match voxilaprevir — full drug profile →
SOF/VEL — full drug profile →

Conditions studied

Hepatitis C Virus Infection — all drugs for Hepatitis C Virus Infection →

Sponsor

Gilead Sciences — full company profile →

Who can join

Adults 18 to 65, any sex, with Hepatitis C Virus Infection. Patients with the condition only — healthy volunteers not accepted.

Results — posted to ClinicalTrials.gov

Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.

Percentage of Participants Experiencing Treatment Emergent Adverse Events Primary · First dose date up to Day 3 plus 30 days

Group	Value	95% CI
Placebo	25.0
Voxilaprevir 50 mg	14.3
Voxilaprevir 100 mg	16.7
Voxilaprevir 300 mg	13.3
Voxilaprevir 100 mg Fed	33.3
Voxilaprevir 100 mg + SOF/VEL 400/100 mg	12.5

Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities Primary · First dose date up to Day 3 plus 30 days

Treatment-emergent laboratory abnormalities were defined as values that increase at least one toxicity grade from baseline. The severity of laboratory abnormalities was assessed as Grade 0, 1 (mild), 2 (moderate), 3 (severe), or 4 (potentially life threatening) using the Common Terminology Criteria for Adverse Events (CTCAE), version 4.03. The most severe graded abnormality from all tests was counted for each participant.

Grade 1

Group	Value	95% CI
Placebo	37.5
Voxilaprevir 50 mg	28.6
Voxilaprevir 100 mg	26.7
Voxilaprevir 300 mg	20.0
Voxilaprevir 100 mg Fed	50.0
Voxilaprevir 100 mg + SOF/VEL 400/100 mg	62.5

Grade 2

Group	Value	95% CI
Placebo	25.0
Voxilaprevir 50 mg	28.6
Voxilaprevir 100 mg	33.3
Voxilaprevir 300 mg	13.3
Voxilaprevir 100 mg Fed	0
Voxilaprevir 100 mg + SOF/VEL 400/100 mg	12.5

Grade 3

Group	Value	95% CI
Placebo	0
Voxilaprevir 50 mg	14.3
Voxilaprevir 100 mg	10.0
Voxilaprevir 300 mg	26.7
Voxilaprevir 100 mg Fed	33.3
Voxilaprevir 100 mg + SOF/VEL 400/100 mg	0

Grade 4

Group	Value	95% CI
Placebo	0
Voxilaprevir 50 mg	0
Voxilaprevir 100 mg	3.3
Voxilaprevir 300 mg	0
Voxilaprevir 100 mg Fed	0
Voxilaprevir 100 mg + SOF/VEL 400/100 mg	0

Antiviral Activity of Voxilaprevir as Measured by Change From Baseline in Plasma HCV RNA Primary · Baseline; Days 4, 5, 6, 7, 8, 10, and Week 48

The outcome measure was assessed to evaluate antiviral activity of voxilaprevir only (cohorts 1 through 6). Data are summarized by treatment/cohort and placebo.

Change at Day 4

Group	Value	95% CI
Placebo (GT 1a, Cohort 1)	-0.12	± 0.136
Voxilaprevir 50 mg (GT 1a, Cohort 1)	-3.81	± 0.516
Voxilaprevir 100 mg (GT 1a, Cohort 1)	-3.97	± 0.608
Voxilaprevir 300 mg (GT 1a, Cohort 1)	-3.33	± 0.902
Placebo (GT 3, Cohort 2)	-0.24	± 0.813
Voxilaprevir 50 mg (GT 3, Cohort 2)	-1.47	± 0.416
Voxilaprevir 100 mg (GT 3, Cohort 2)	-3.20	± 0.364
Voxilaprevir 300 mg (GT 3, Cohort 2)	-3.57	± 0.483
Placebo (GT 2, Cohort 3)	0.00	± 0.104
Voxilaprevir 100 mg (GT 2, Cohort 3)	-3.41	± 0.444
Voxilaprevir 100 mg (GT 4, Cohort 4)	-3.50	± 0.677
Voxilaprevir 100 mg (GT 1b, Cohort 5)	-3.57	± 0.227

Change at Day 5

Group	Value	95% CI
Placebo (GT 1a, Cohort 1)	-0.20	± 0.519
Voxilaprevir 50 mg (GT 1a, Cohort 1)	-3.58	± 1.104
Voxilaprevir 100 mg (GT 1a, Cohort 1)	-4.03	± 0.594
Voxilaprevir 300 mg (GT 1a, Cohort 1)	-3.37	± 0.894
Placebo (GT 3, Cohort 2)	-0.17	± 0.285
Voxilaprevir 50 mg (GT 3, Cohort 2)	-1.43	± 0.606
Voxilaprevir 100 mg (GT 3, Cohort 2)	-3.00	± 0.470
Voxilaprevir 300 mg (GT 3, Cohort 2)	-3.28	± 0.515
Placebo (GT 2, Cohort 3)	-0.12	± 0.151
Voxilaprevir 100 mg (GT 2, Cohort 3)	-3.37	± 0.480
Voxilaprevir 100 mg (GT 4, Cohort 4)	-3.61	± 0.702
Voxilaprevir 100 mg (GT 1b, Cohort 5)	-3.60	± 0.390

Change at Day 6

Group	Value	95% CI
Placebo (GT 1a, Cohort 1)	-0.21	± 0.479
Voxilaprevir 50 mg (GT 1a, Cohort 1)	-3.45	± 0.829
Voxilaprevir 100 mg (GT 1a, Cohort 1)	-3.78	± 0.710
Voxilaprevir 300 mg (GT 1a, Cohort 1)	-3.47	± 0.763
Placebo (GT 3, Cohort 2)	-0.06	± 0.051
Voxilaprevir 50 mg (GT 3, Cohort 2)	-1.06	± 0.632
Voxilaprevir 100 mg (GT 3, Cohort 2)	-2.52	± 0.739
Voxilaprevir 300 mg (GT 3, Cohort 2)	-3.13	± 0.736
Placebo (GT 2, Cohort 3)	-0.04	± 0.139
Voxilaprevir 100 mg (GT 2, Cohort 3)	-3.22	± 0.689
Voxilaprevir 100 mg (GT 4, Cohort 4)	-3.69	± 0.879
Voxilaprevir 100 mg (GT 1b, Cohort 5)	-3.61	± 0.601

Change at Day 7

Group	Value	95% CI
Placebo (GT 1a, Cohort 1)	0.01	± 0.340
Voxilaprevir 50 mg (GT 1a, Cohort 1)	-3.15	± 0.973
Voxilaprevir 100 mg (GT 1a, Cohort 1)	-3.88	± 0.729
Voxilaprevir 300 mg (GT 1a, Cohort 1)	-3.48	± 0.695
Placebo (GT 3, Cohort 2)	0.02	± 0.089
Voxilaprevir 50 mg (GT 3, Cohort 2)	-0.76	± 0.352
Voxilaprevir 100 mg (GT 3, Cohort 2)	-2.00	± 0.378
Voxilaprevir 300 mg (GT 3, Cohort 2)	-2.89	± 0.763
Placebo (GT 2, Cohort 3)	-0.05	± 0.058
Voxilaprevir 100 mg (GT 2, Cohort 3)	-2.80	± 0.494
Voxilaprevir 100 mg (GT 4, Cohort 4)	-3.70	± 0.877
Voxilaprevir 100 mg (GT 1b, Cohort 5)	-3.42	± 0.710

Change at Day 8

Group	Value	95% CI
Placebo (GT 1a, Cohort 1)	0.13	± 0.260
Voxilaprevir 50 mg (GT 1a, Cohort 1)	-2.92	± 1.069
Voxilaprevir 100 mg (GT 1a, Cohort 1)	-3.54	± 0.663
Voxilaprevir 300 mg (GT 1a, Cohort 1)	-3.23	± 0.726
Placebo (GT 3, Cohort 2)	-0.14	± 0.158
Voxilaprevir 50 mg (GT 3, Cohort 2)	-0.53	± 0.379
Voxilaprevir 100 mg (GT 3, Cohort 2)	-1.79	± 0.627
Voxilaprevir 300 mg (GT 3, Cohort 2)	-2.74	± 0.916
Placebo (GT 2, Cohort 3)	-0.05	± 0.090
Voxilaprevir 100 mg (GT 2, Cohort 3)	-2.48	± 0.355
Voxilaprevir 100 mg (GT 4, Cohort 4)	-3.53	± 0.637
Voxilaprevir 100 mg (GT 1b, Cohort 5)	-3.27	± 0.627

Change at Day 10

Group	Value	95% CI
Placebo (GT 1a, Cohort 1)	-0.06	± 0.091
Voxilaprevir 50 mg (GT 1a, Cohort 1)	-2.69	± 1.116
Voxilaprevir 100 mg (GT 1a, Cohort 1)	-3.33	± 0.756
Voxilaprevir 300 mg (GT 1a, Cohort 1)	-2.97	± 0.918
Placebo (GT 3, Cohort 2)	-0.23	± 0.180
Voxilaprevir 50 mg (GT 3, Cohort 2)	-0.28	± 0.330
Voxilaprevir 100 mg (GT 3, Cohort 2)	-1.18	± 1.055
Voxilaprevir 300 mg (GT 3, Cohort 2)	-2.17	± 1.394
Placebo (GT 2, Cohort 3)	-0.13	± 0.022
Voxilaprevir 100 mg (GT 2, Cohort 3)	-2.28	± 0.469
Voxilaprevir 100 mg (GT 4, Cohort 4)	-3.61	± 0.674
Voxilaprevir 100 mg (GT 1b, Cohort 5)	-3.08	± 0.740

Change at Week 48

Group	Value	95% CI
Placebo (GT 1a, Cohort 1)	0.41	± 0.873
Voxilaprevir 50 mg (GT 1a, Cohort 1)	0.08	± 0.337
Voxilaprevir 100 mg (GT 1a, Cohort 1)	-0.80	± 2.094
Voxilaprevir 300 mg (GT 1a, Cohort 1)	-0.73	± 2.352
Placebo (GT 3, Cohort 2)	0.41
Voxilaprevir 50 mg (GT 3, Cohort 2)	-0.03	± 0.221
Voxilaprevir 100 mg (GT 3, Cohort 2)	0.54
Voxilaprevir 300 mg (GT 3, Cohort 2)	0.06	± 0.370
Placebo (GT 2, Cohort 3)	-0.02
Voxilaprevir 100 mg (GT 2, Cohort 3)	-0.02
Voxilaprevir 100 mg (GT 4, Cohort 4)	0.18	± 0.247
Voxilaprevir 100 mg (GT 1b, Cohort 5)	-0.57	± 2.389

Antiviral Activity of Voxilaprevir as Measured by Absolute HCV RNA Level Through Week 48 Secondary · Baseline (Pre Day 1 Dose); Days 4, 5, 6, 7, 8, 10, and Week 48

The outcome measure was assessed to evaluate antiviral activity of voxilaprevir only (cohorts 1 through 6).

Pre Day 1 Dose

Group	Value	95% CI
Placebo (GT 1a, Cohort 1)	6.73	± 0.307
Voxilaprevir 50 mg (GT 1a, Cohort 1)	6.30	± 0.497
Voxilaprevir 100 mg (GT 1a, Cohort 1)	6.35	± 0.526
Voxilaprevir 300 mg (GT 1a, Cohort 1)	6.05	± 0.558
Placebo (GT 3, Cohort 2)	6.11	± 0.480
Voxilaprevir 50 mg (GT 3, Cohort 2)	5.61	± 0.612
Voxilaprevir 100 mg (GT 3, Cohort 2)	6.75	± 0.346
Voxilaprevir 300 mg (GT 3, Cohort 2)	6.01	± 0.773
Placebo (GT 2, Cohort 3)	6.71	± 0.059
Voxilaprevir 100 mg (GT 2, Cohort 3)	6.24	± 0.394
Voxilaprevir 100 mg (GT 4, Cohort 4)	6.16	± 0.730
Voxilaprevir 100 mg (GT 1b, Cohort 5)	6.23	± 0.608

Day 4

Group	Value	95% CI
Placebo (GT 1a, Cohort 1)	6.62	± 0.378
Voxilaprevir 50 mg (GT 1a, Cohort 1)	2.56	± 0.705
Voxilaprevir 100 mg (GT 1a, Cohort 1)	2.38	± 0.759
Voxilaprevir 300 mg (GT 1a, Cohort 1)	2.72	± 0.943
Placebo (GT 3, Cohort 2)	5.87	± 0.332
Voxilaprevir 50 mg (GT 3, Cohort 2)	4.22	± 0.878
Voxilaprevir 100 mg (GT 3, Cohort 2)	3.54	± 0.455
Voxilaprevir 300 mg (GT 3, Cohort 2)	2.44	± 0.693
Placebo (GT 2, Cohort 3)	6.71	± 0.164
Voxilaprevir 100 mg (GT 2, Cohort 3)	2.83	± 0.611
Voxilaprevir 100 mg (GT 4, Cohort 4)	2.65	± 0.533
Voxilaprevir 100 mg (GT 1b, Cohort 5)	2.67	± 0.500

Day 5

Group	Value	95% CI
Placebo (GT 1a, Cohort 1)	6.53	± 0.426
Voxilaprevir 50 mg (GT 1a, Cohort 1)	2.73	± 1.203
Voxilaprevir 100 mg (GT 1a, Cohort 1)	2.33	± 0.643
Voxilaprevir 300 mg (GT 1a, Cohort 1)	2.67	± 0.947
Placebo (GT 3, Cohort 2)	5.94	± 0.195
Voxilaprevir 50 mg (GT 3, Cohort 2)	4.19	± 1.104
Voxilaprevir 100 mg (GT 3, Cohort 2)	3.75	± 0.455
Voxilaprevir 300 mg (GT 3, Cohort 2)	2.73	± 0.780
Placebo (GT 2, Cohort 3)	6.59	± 0.210
Voxilaprevir 100 mg (GT 2, Cohort 3)	2.87	± 0.603
Voxilaprevir 100 mg (GT 4, Cohort 4)	2.55	± 0.549
Voxilaprevir 100 mg (GT 1b, Cohort 5)	2.63	± 0.764

Day 6

Group	Value	95% CI
Placebo (GT 1a, Cohort 1)	6.52	± 0.320
Voxilaprevir 50 mg (GT 1a, Cohort 1)	2.85	± 1.000
Voxilaprevir 100 mg (GT 1a, Cohort 1)	2.57	± 1.028
Voxilaprevir 300 mg (GT 1a, Cohort 1)	2.57	± 0.818
Placebo (GT 3, Cohort 2)	6.05	± 0.532
Voxilaprevir 50 mg (GT 3, Cohort 2)	4.55	± 1.203
Voxilaprevir 100 mg (GT 3, Cohort 2)	4.23	± 0.604
Voxilaprevir 300 mg (GT 3, Cohort 2)	2.88	± 0.882
Placebo (GT 2, Cohort 3)	6.68	± 0.199
Voxilaprevir 100 mg (GT 2, Cohort 3)	3.02	± 0.754
Voxilaprevir 100 mg (GT 4, Cohort 4)	2.46	± 0.300
Voxilaprevir 100 mg (GT 1b, Cohort 5)	2.85	± 0.685

Day 7

Group	Value	95% CI
Placebo (GT 1a, Cohort 1)	6.74	± 0.059
Voxilaprevir 50 mg (GT 1a, Cohort 1)	3.15	± 1.268
Voxilaprevir 100 mg (GT 1a, Cohort 1)	2.47	± 0.821
Voxilaprevir 300 mg (GT 1a, Cohort 1)	2.56	± 0.714
Placebo (GT 3, Cohort 2)	6.13	± 0.569
Voxilaprevir 50 mg (GT 3, Cohort 2)	4.85	± 0.886
Voxilaprevir 100 mg (GT 3, Cohort 2)	4.75	± 0.268
Voxilaprevir 300 mg (GT 3, Cohort 2)	3.12	± 0.991
Placebo (GT 2, Cohort 3)	6.67	± 0.001
Voxilaprevir 100 mg (GT 2, Cohort 3)	3.44	± 0.613
Voxilaprevir 100 mg (GT 4, Cohort 4)	2.45	± 0.359
Voxilaprevir 100 mg (GT 1b, Cohort 5)	2.82	± 1.111

Day 8

Group	Value	95% CI
Placebo (GT 1a, Cohort 1)	6.86	± 0.144
Voxilaprevir 50 mg (GT 1a, Cohort 1)	3.38	± 1.019
Voxilaprevir 100 mg (GT 1a, Cohort 1)	2.81	± 0.901
Voxilaprevir 300 mg (GT 1a, Cohort 1)	2.81	± 0.671
Placebo (GT 3, Cohort 2)	5.97	± 0.323
Voxilaprevir 50 mg (GT 3, Cohort 2)	5.08	± 0.655
Voxilaprevir 100 mg (GT 3, Cohort 2)	4.96	± 0.531
Voxilaprevir 300 mg (GT 3, Cohort 2)	3.27	± 1.100
Placebo (GT 2, Cohort 3)	6.66	± 0.031
Voxilaprevir 100 mg (GT 2, Cohort 3)	3.76	± 0.497
Voxilaprevir 100 mg (GT 4, Cohort 4)	2.62	± 0.278
Voxilaprevir 100 mg (GT 1b, Cohort 5)	2.96	± 1.111

Day 10

Group	Value	95% CI
Placebo (GT 1a, Cohort 1)	6.68	± 0.263
Voxilaprevir 50 mg (GT 1a, Cohort 1)	3.61	± 1.041
Voxilaprevir 100 mg (GT 1a, Cohort 1)	3.03	± 0.857
Voxilaprevir 300 mg (GT 1a, Cohort 1)	3.07	± 0.887
Placebo (GT 3, Cohort 2)	5.88	± 0.300
Voxilaprevir 50 mg (GT 3, Cohort 2)	5.43	± 0.803
Voxilaprevir 100 mg (GT 3, Cohort 2)	5.56	± 0.987
Voxilaprevir 300 mg (GT 3, Cohort 2)	3.83	± 1.417
Placebo (GT 2, Cohort 3)	6.58	± 0.081
Voxilaprevir 100 mg (GT 2, Cohort 3)	3.96	± 0.555
Voxilaprevir 100 mg (GT 4, Cohort 4)	2.54	± 0.553
Voxilaprevir 100 mg (GT 1b, Cohort 5)	3.15	± 1.210

Week 48

Group	Value	95% CI
Placebo (GT 1a, Cohort 1)	6.97	± 0.488
Voxilaprevir 50 mg (GT 1a, Cohort 1)	6.29	± 0.825
Voxilaprevir 100 mg (GT 1a, Cohort 1)	5.55	± 2.007
Voxilaprevir 300 mg (GT 1a, Cohort 1)	5.20	± 2.085
Placebo (GT 3, Cohort 2)	6.18
Voxilaprevir 50 mg (GT 3, Cohort 2)	5.13	± 0.207
Voxilaprevir 100 mg (GT 3, Cohort 2)	7.29
Voxilaprevir 300 mg (GT 3, Cohort 2)	6.38	± 1.479
Placebo (GT 2, Cohort 3)	6.65
Voxilaprevir 100 mg (GT 2, Cohort 3)	6.13
Voxilaprevir 100 mg (GT 4, Cohort 4)	6.34	± 0.696
Voxilaprevir 100 mg (GT 1b, Cohort 5)	5.65	± 2.473

Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA Secondary · Baseline; Days 4, 5, 6, 7, 8, 10, and Week 48

Categorical declines from baseline were summarized by the number of participants with a \< 1, ≥ 1 to \<2, ≥ 2 to \<3, or ≥ 3 log10 IU/mL decrease in HCV RNA from baseline to each postdose assessment up to Week 48 by treatment/cohort and placebo. The outcome measure was assessed to evaluate antiviral activity of voxilaprevir only (cohorts 1 through 6).

Day 4

Group	Value	95% CI
Placebo (GT 1a, Cohort 1)	0
Voxilaprevir 50 mg (GT 1a, Cohort 1)	1
Voxilaprevir 100 mg (GT 1a, Cohort 1)	0
Voxilaprevir 300 mg (GT 1a, Cohort 1)	0
Placebo (GT 3, Cohort 2)	0
Voxilaprevir 50 mg (GT 3, Cohort 2)	1
Voxilaprevir 100 mg (GT 3, Cohort 2)	1
Voxilaprevir 300 mg (GT 3, Cohort 2)	0
Placebo (GT 2, Cohort 3)	0
Voxilaprevir 100 mg (GT 2, Cohort 3)	0
Voxilaprevir 100 mg (GT 4, Cohort 4)	0
Voxilaprevir 100 mg (GT 1b, Cohort 5)	0
Placebo (GT 1a, Cohort 1)	4
Voxilaprevir 50 mg (GT 1a, Cohort 1)	0
Voxilaprevir 100 mg (GT 1a, Cohort 1)	0
Voxilaprevir 300 mg (GT 1a, Cohort 1)	0
Placebo (GT 3, Cohort 2)	2
Voxilaprevir 50 mg (GT 3, Cohort 2)	0
Voxilaprevir 100 mg (GT 3, Cohort 2)	0
Voxilaprevir 300 mg (GT 3, Cohort 2)	0
Placebo (GT 2, Cohort 3)	2
Voxilaprevir 100 mg (GT 2, Cohort 3)	0
Voxilaprevir 100 mg (GT 4, Cohort 4)	0
Voxilaprevir 100 mg (GT 1b, Cohort 5)	0
Placebo (GT 1a, Cohort 1)	0
Voxilaprevir 50 mg (GT 1a, Cohort 1)	0
Voxilaprevir 100 mg (GT 1a, Cohort 1)	0
Voxilaprevir 300 mg (GT 1a, Cohort 1)	1
Placebo (GT 3, Cohort 2)	0
Voxilaprevir 50 mg (GT 3, Cohort 2)	4
Voxilaprevir 100 mg (GT 3, Cohort 2)	0
Voxilaprevir 300 mg (GT 3, Cohort 2)	0
Placebo (GT 2, Cohort 3)	0
Voxilaprevir 100 mg (GT 2, Cohort 3)	0
Voxilaprevir 100 mg (GT 4, Cohort 4)	0
Voxilaprevir 100 mg (GT 1b, Cohort 5)	0
Placebo (GT 1a, Cohort 1)	0
Voxilaprevir 50 mg (GT 1a, Cohort 1)	0
Voxilaprevir 100 mg (GT 1a, Cohort 1)	1
Voxilaprevir 300 mg (GT 1a, Cohort 1)	0
Placebo (GT 3, Cohort 2)	0
Voxilaprevir 50 mg (GT 3, Cohort 2)	1
Voxilaprevir 100 mg (GT 3, Cohort 2)	1
Voxilaprevir 300 mg (GT 3, Cohort 2)	1
Placebo (GT 2, Cohort 3)	0
Voxilaprevir 100 mg (GT 2, Cohort 3)	1
Voxilaprevir 100 mg (GT 4, Cohort 4)	1
Voxilaprevir 100 mg (GT 1b, Cohort 5)	0

Day 5

Group	Value	95% CI
Placebo (GT 1a, Cohort 1)	0
Voxilaprevir 50 mg (GT 1a, Cohort 1)	0
Voxilaprevir 100 mg (GT 1a, Cohort 1)	0
Voxilaprevir 300 mg (GT 1a, Cohort 1)	1
Placebo (GT 3, Cohort 2)	0
Voxilaprevir 50 mg (GT 3, Cohort 2)	0
Voxilaprevir 100 mg (GT 3, Cohort 2)	1
Voxilaprevir 300 mg (GT 3, Cohort 2)	0
Placebo (GT 2, Cohort 3)	0
Voxilaprevir 100 mg (GT 2, Cohort 3)	0
Voxilaprevir 100 mg (GT 4, Cohort 4)	0
Voxilaprevir 100 mg (GT 1b, Cohort 5)	0
Placebo (GT 1a, Cohort 1)	4
Voxilaprevir 50 mg (GT 1a, Cohort 1)	0
Voxilaprevir 100 mg (GT 1a, Cohort 1)	0
Voxilaprevir 300 mg (GT 1a, Cohort 1)	0
Placebo (GT 3, Cohort 2)	2
Voxilaprevir 50 mg (GT 3, Cohort 2)	1
Voxilaprevir 100 mg (GT 3, Cohort 2)	0
Voxilaprevir 300 mg (GT 3, Cohort 2)	0
Placebo (GT 2, Cohort 3)	2
Voxilaprevir 100 mg (GT 2, Cohort 3)	0
Voxilaprevir 100 mg (GT 4, Cohort 4)	0
Voxilaprevir 100 mg (GT 1b, Cohort 5)	0
Placebo (GT 1a, Cohort 1)	0
Voxilaprevir 50 mg (GT 1a, Cohort 1)	1
Voxilaprevir 100 mg (GT 1a, Cohort 1)	0
Voxilaprevir 300 mg (GT 1a, Cohort 1)	1
Placebo (GT 3, Cohort 2)	0
Voxilaprevir 50 mg (GT 3, Cohort 2)	4
Voxilaprevir 100 mg (GT 3, Cohort 2)	0
Voxilaprevir 300 mg (GT 3, Cohort 2)	0
Placebo (GT 2, Cohort 3)	0
Voxilaprevir 100 mg (GT 2, Cohort 3)	0
Voxilaprevir 100 mg (GT 4, Cohort 4)	0
Voxilaprevir 100 mg (GT 1b, Cohort 5)	0
Placebo (GT 1a, Cohort 1)	0
Voxilaprevir 50 mg (GT 1a, Cohort 1)	1
Voxilaprevir 100 mg (GT 1a, Cohort 1)	0
Voxilaprevir 300 mg (GT 1a, Cohort 1)	0
Placebo (GT 3, Cohort 2)	0
Voxilaprevir 50 mg (GT 3, Cohort 2)	1
Voxilaprevir 100 mg (GT 3, Cohort 2)	2
Voxilaprevir 300 mg (GT 3, Cohort 2)	2
Placebo (GT 2, Cohort 3)	0
Voxilaprevir 100 mg (GT 2, Cohort 3)	2
Voxilaprevir 100 mg (GT 4, Cohort 4)	1
Voxilaprevir 100 mg (GT 1b, Cohort 5)	0

Day 6

Group	Value	95% CI
Placebo (GT 1a, Cohort 1)	0
Voxilaprevir 50 mg (GT 1a, Cohort 1)	0
Voxilaprevir 100 mg (GT 1a, Cohort 1)	0
Voxilaprevir 300 mg (GT 1a, Cohort 1)	1
Placebo (GT 3, Cohort 2)	0
Voxilaprevir 50 mg (GT 3, Cohort 2)	0
Voxilaprevir 100 mg (GT 3, Cohort 2)	1
Voxilaprevir 300 mg (GT 3, Cohort 2)	0
Placebo (GT 2, Cohort 3)	0
Voxilaprevir 100 mg (GT 2, Cohort 3)	0
Voxilaprevir 100 mg (GT 4, Cohort 4)	0
Voxilaprevir 100 mg (GT 1b, Cohort 5)	1
Placebo (GT 1a, Cohort 1)	4
Voxilaprevir 50 mg (GT 1a, Cohort 1)	0
Voxilaprevir 100 mg (GT 1a, Cohort 1)	0
Voxilaprevir 300 mg (GT 1a, Cohort 1)	0
Placebo (GT 3, Cohort 2)	2
Voxilaprevir 50 mg (GT 3, Cohort 2)	2
Voxilaprevir 100 mg (GT 3, Cohort 2)	0
Voxilaprevir 300 mg (GT 3, Cohort 2)	0
Placebo (GT 2, Cohort 3)	2
Voxilaprevir 100 mg (GT 2, Cohort 3)	0
Voxilaprevir 100 mg (GT 4, Cohort 4)	0
Voxilaprevir 100 mg (GT 1b, Cohort 5)	0
Placebo (GT 1a, Cohort 1)	0
Voxilaprevir 50 mg (GT 1a, Cohort 1)	1
Voxilaprevir 100 mg (GT 1a, Cohort 1)	0
Voxilaprevir 300 mg (GT 1a, Cohort 1)	1
Placebo (GT 3, Cohort 2)	0
Voxilaprevir 50 mg (GT 3, Cohort 2)	4
Voxilaprevir 100 mg (GT 3, Cohort 2)	1
Voxilaprevir 300 mg (GT 3, Cohort 2)	1
Placebo (GT 2, Cohort 3)	0
Voxilaprevir 100 mg (GT 2, Cohort 3)	0
Voxilaprevir 100 mg (GT 4, Cohort 4)	0
Voxilaprevir 100 mg (GT 1b, Cohort 5)	0
Placebo (GT 1a, Cohort 1)	0
Voxilaprevir 50 mg (GT 1a, Cohort 1)	0
Voxilaprevir 100 mg (GT 1a, Cohort 1)	1
Voxilaprevir 300 mg (GT 1a, Cohort 1)	0
Placebo (GT 3, Cohort 2)	0
Voxilaprevir 50 mg (GT 3, Cohort 2)	0
Voxilaprevir 100 mg (GT 3, Cohort 2)	3
Voxilaprevir 300 mg (GT 3, Cohort 2)	1
Placebo (GT 2, Cohort 3)	0
Voxilaprevir 100 mg (GT 2, Cohort 3)	2
Voxilaprevir 100 mg (GT 4, Cohort 4)	1
Voxilaprevir 100 mg (GT 1b, Cohort 5)	1

Day 7

Group	Value	95% CI
Placebo (GT 1a, Cohort 1)	0
Voxilaprevir 50 mg (GT 1a, Cohort 1)	0
Voxilaprevir 100 mg (GT 1a, Cohort 1)	0
Voxilaprevir 300 mg (GT 1a, Cohort 1)	1
Placebo (GT 3, Cohort 2)	0
Voxilaprevir 50 mg (GT 3, Cohort 2)	0
Voxilaprevir 100 mg (GT 3, Cohort 2)	1
Voxilaprevir 300 mg (GT 3, Cohort 2)	0
Placebo (GT 2, Cohort 3)	0
Voxilaprevir 100 mg (GT 2, Cohort 3)	0
Voxilaprevir 100 mg (GT 4, Cohort 4)	0
Voxilaprevir 100 mg (GT 1b, Cohort 5)	0
Placebo (GT 1a, Cohort 1)	4
Voxilaprevir 50 mg (GT 1a, Cohort 1)	0
Voxilaprevir 100 mg (GT 1a, Cohort 1)	0
Voxilaprevir 300 mg (GT 1a, Cohort 1)	0
Placebo (GT 3, Cohort 2)	2
Voxilaprevir 50 mg (GT 3, Cohort 2)	4
Voxilaprevir 100 mg (GT 3, Cohort 2)	0
Voxilaprevir 300 mg (GT 3, Cohort 2)	0
Placebo (GT 2, Cohort 3)	2
Voxilaprevir 100 mg (GT 2, Cohort 3)	0
Voxilaprevir 100 mg (GT 4, Cohort 4)	0
Voxilaprevir 100 mg (GT 1b, Cohort 5)	0
Placebo (GT 1a, Cohort 1)	0
Voxilaprevir 50 mg (GT 1a, Cohort 1)	2
Voxilaprevir 100 mg (GT 1a, Cohort 1)	0
Voxilaprevir 300 mg (GT 1a, Cohort 1)	0
Placebo (GT 3, Cohort 2)	0
Voxilaprevir 50 mg (GT 3, Cohort 2)	2
Voxilaprevir 100 mg (GT 3, Cohort 2)	3
Voxilaprevir 300 mg (GT 3, Cohort 2)	1
Placebo (GT 2, Cohort 3)	0
Voxilaprevir 100 mg (GT 2, Cohort 3)	0
Voxilaprevir 100 mg (GT 4, Cohort 4)	0
Voxilaprevir 100 mg (GT 1b, Cohort 5)	0
Placebo (GT 1a, Cohort 1)	0
Voxilaprevir 50 mg (GT 1a, Cohort 1)	0
Voxilaprevir 100 mg (GT 1a, Cohort 1)	1
Voxilaprevir 300 mg (GT 1a, Cohort 1)	1
Placebo (GT 3, Cohort 2)	0
Voxilaprevir 50 mg (GT 3, Cohort 2)	0
Voxilaprevir 100 mg (GT 3, Cohort 2)	2
Voxilaprevir 300 mg (GT 3, Cohort 2)	2
Placebo (GT 2, Cohort 3)	0
Voxilaprevir 100 mg (GT 2, Cohort 3)	3
Voxilaprevir 100 mg (GT 4, Cohort 4)	1
Voxilaprevir 100 mg (GT 1b, Cohort 5)	2

Day 8

Group	Value	95% CI
Placebo (GT 1a, Cohort 1)	0
Voxilaprevir 50 mg (GT 1a, Cohort 1)	0
Voxilaprevir 100 mg (GT 1a, Cohort 1)	0
Voxilaprevir 300 mg (GT 1a, Cohort 1)	1
Placebo (GT 3, Cohort 2)	0
Voxilaprevir 50 mg (GT 3, Cohort 2)	0
Voxilaprevir 100 mg (GT 3, Cohort 2)	1
Voxilaprevir 300 mg (GT 3, Cohort 2)	0
Placebo (GT 2, Cohort 3)	0
Voxilaprevir 100 mg (GT 2, Cohort 3)	0
Voxilaprevir 100 mg (GT 4, Cohort 4)	0
Voxilaprevir 100 mg (GT 1b, Cohort 5)	0
Placebo (GT 1a, Cohort 1)	4
Voxilaprevir 50 mg (GT 1a, Cohort 1)	0
Voxilaprevir 100 mg (GT 1a, Cohort 1)	0
Voxilaprevir 300 mg (GT 1a, Cohort 1)	0
Placebo (GT 3, Cohort 2)	2
Voxilaprevir 50 mg (GT 3, Cohort 2)	6
Voxilaprevir 100 mg (GT 3, Cohort 2)	0
Voxilaprevir 300 mg (GT 3, Cohort 2)	1
Placebo (GT 2, Cohort 3)	2
Voxilaprevir 100 mg (GT 2, Cohort 3)	0
Voxilaprevir 100 mg (GT 4, Cohort 4)	0
Voxilaprevir 100 mg (GT 1b, Cohort 5)	0
Placebo (GT 1a, Cohort 1)	0
Voxilaprevir 50 mg (GT 1a, Cohort 1)	2
Voxilaprevir 100 mg (GT 1a, Cohort 1)	0
Voxilaprevir 300 mg (GT 1a, Cohort 1)	0
Placebo (GT 3, Cohort 2)	0
Voxilaprevir 50 mg (GT 3, Cohort 2)	0
Voxilaprevir 100 mg (GT 3, Cohort 2)	4
Voxilaprevir 300 mg (GT 3, Cohort 2)	0
Placebo (GT 2, Cohort 3)	0
Voxilaprevir 100 mg (GT 2, Cohort 3)	0
Voxilaprevir 100 mg (GT 4, Cohort 4)	0
Voxilaprevir 100 mg (GT 1b, Cohort 5)	0
Placebo (GT 1a, Cohort 1)	0
Voxilaprevir 50 mg (GT 1a, Cohort 1)	2
Voxilaprevir 100 mg (GT 1a, Cohort 1)	1
Voxilaprevir 300 mg (GT 1a, Cohort 1)	3
Placebo (GT 3, Cohort 2)	0
Voxilaprevir 50 mg (GT 3, Cohort 2)	0
Voxilaprevir 100 mg (GT 3, Cohort 2)	1
Voxilaprevir 300 mg (GT 3, Cohort 2)	2
Placebo (GT 2, Cohort 3)	0
Voxilaprevir 100 mg (GT 2, Cohort 3)	6
Voxilaprevir 100 mg (GT 4, Cohort 4)	1
Voxilaprevir 100 mg (GT 1b, Cohort 5)	2

Day 10

Group	Value	95% CI
Placebo (GT 1a, Cohort 1)	0
Voxilaprevir 50 mg (GT 1a, Cohort 1)	0
Voxilaprevir 100 mg (GT 1a, Cohort 1)	0
Voxilaprevir 300 mg (GT 1a, Cohort 1)	1
Placebo (GT 3, Cohort 2)	0
Voxilaprevir 50 mg (GT 3, Cohort 2)	1
Voxilaprevir 100 mg (GT 3, Cohort 2)	1
Voxilaprevir 300 mg (GT 3, Cohort 2)	0
Placebo (GT 2, Cohort 3)	0
Voxilaprevir 100 mg (GT 2, Cohort 3)	0
Voxilaprevir 100 mg (GT 4, Cohort 4)	0
Voxilaprevir 100 mg (GT 1b, Cohort 5)	0
Placebo (GT 1a, Cohort 1)	4
Voxilaprevir 50 mg (GT 1a, Cohort 1)	0
Voxilaprevir 100 mg (GT 1a, Cohort 1)	0
Voxilaprevir 300 mg (GT 1a, Cohort 1)	0
Placebo (GT 3, Cohort 2)	2
Voxilaprevir 50 mg (GT 3, Cohort 2)	5
Voxilaprevir 100 mg (GT 3, Cohort 2)	2
Voxilaprevir 300 mg (GT 3, Cohort 2)	1
Placebo (GT 2, Cohort 3)	2
Voxilaprevir 100 mg (GT 2, Cohort 3)	0
Voxilaprevir 100 mg (GT 4, Cohort 4)	0
Voxilaprevir 100 mg (GT 1b, Cohort 5)	0
Placebo (GT 1a, Cohort 1)	0
Voxilaprevir 50 mg (GT 1a, Cohort 1)	3
Voxilaprevir 100 mg (GT 1a, Cohort 1)	1
Voxilaprevir 300 mg (GT 1a, Cohort 1)	1
Placebo (GT 3, Cohort 2)	0
Voxilaprevir 50 mg (GT 3, Cohort 2)	0
Voxilaprevir 100 mg (GT 3, Cohort 2)	2
Voxilaprevir 300 mg (GT 3, Cohort 2)	2
Placebo (GT 2, Cohort 3)	0
Voxilaprevir 100 mg (GT 2, Cohort 3)	2
Voxilaprevir 100 mg (GT 4, Cohort 4)	0
Voxilaprevir 100 mg (GT 1b, Cohort 5)	1
Placebo (GT 1a, Cohort 1)	0
Voxilaprevir 50 mg (GT 1a, Cohort 1)	2
Voxilaprevir 100 mg (GT 1a, Cohort 1)	0
Voxilaprevir 300 mg (GT 1a, Cohort 1)	3
Placebo (GT 3, Cohort 2)	0
Voxilaprevir 50 mg (GT 3, Cohort 2)	0
Voxilaprevir 100 mg (GT 3, Cohort 2)	1
Voxilaprevir 300 mg (GT 3, Cohort 2)	1
Placebo (GT 2, Cohort 3)	0
Voxilaprevir 100 mg (GT 2, Cohort 3)	4
Voxilaprevir 100 mg (GT 4, Cohort 4)	0
Voxilaprevir 100 mg (GT 1b, Cohort 5)	1

Week 48

Group	Value	95% CI
Placebo (GT 1a, Cohort 1)	2
Voxilaprevir 50 mg (GT 1a, Cohort 1)	4
Voxilaprevir 100 mg (GT 1a, Cohort 1)	1
Voxilaprevir 300 mg (GT 1a, Cohort 1)	2
Placebo (GT 3, Cohort 2)	1
Voxilaprevir 50 mg (GT 3, Cohort 2)	3
Voxilaprevir 100 mg (GT 3, Cohort 2)	5
Voxilaprevir 300 mg (GT 3, Cohort 2)	5
Placebo (GT 2, Cohort 3)	1
Voxilaprevir 100 mg (GT 2, Cohort 3)	5
Voxilaprevir 100 mg (GT 4, Cohort 4)	0
Voxilaprevir 100 mg (GT 1b, Cohort 5)	1
Placebo (GT 1a, Cohort 1)	2
Voxilaprevir 50 mg (GT 1a, Cohort 1)	4
Voxilaprevir 100 mg (GT 1a, Cohort 1)	6
Voxilaprevir 300 mg (GT 1a, Cohort 1)	5
Placebo (GT 3, Cohort 2)	1
Voxilaprevir 50 mg (GT 3, Cohort 2)	3
Voxilaprevir 100 mg (GT 3, Cohort 2)	1
Voxilaprevir 300 mg (GT 3, Cohort 2)	2
Placebo (GT 2, Cohort 3)	1
Voxilaprevir 100 mg (GT 2, Cohort 3)	1
Voxilaprevir 100 mg (GT 4, Cohort 4)	4
Voxilaprevir 100 mg (GT 1b, Cohort 5)	4
Placebo (GT 1a, Cohort 1)	0
Voxilaprevir 50 mg (GT 1a, Cohort 1)	0
Voxilaprevir 100 mg (GT 1a, Cohort 1)	0
Voxilaprevir 300 mg (GT 1a, Cohort 1)	0
Placebo (GT 3, Cohort 2)	0
Voxilaprevir 50 mg (GT 3, Cohort 2)	0
Voxilaprevir 100 mg (GT 3, Cohort 2)	0
Voxilaprevir 300 mg (GT 3, Cohort 2)	0
Placebo (GT 2, Cohort 3)	0
Voxilaprevir 100 mg (GT 2, Cohort 3)	0
Voxilaprevir 100 mg (GT 4, Cohort 4)	0
Voxilaprevir 100 mg (GT 1b, Cohort 5)	0
Placebo (GT 1a, Cohort 1)	0
Voxilaprevir 50 mg (GT 1a, Cohort 1)	0
Voxilaprevir 100 mg (GT 1a, Cohort 1)	0
Voxilaprevir 300 mg (GT 1a, Cohort 1)	0
Placebo (GT 3, Cohort 2)	0
Voxilaprevir 50 mg (GT 3, Cohort 2)	0
Voxilaprevir 100 mg (GT 3, Cohort 2)	0
Voxilaprevir 300 mg (GT 3, Cohort 2)	0
Placebo (GT 2, Cohort 3)	0
Voxilaprevir 100 mg (GT 2, Cohort 3)	0
Voxilaprevir 100 mg (GT 4, Cohort 4)	0
Voxilaprevir 100 mg (GT 1b, Cohort 5)	0

Percentage of Participants Who Have HCV RNA < Lower Limit of Quantitation (LLOQ) Detected, and < LLOQ Target Not Detected (TND) Secondary · Days 4, 5, 6, 7, 8, 10, and Week 48

The lower limit of quantitation (LLOQ) detection for HCV RNA levels was 15 IU/mL. HCV detected means calculated HCV RNA level is below LLOQ of the assay. The outcome measure was assessed to evaluate antiviral activity of voxilaprevir only (cohorts 1 through 6).

Day 4 < LLOQ detected

Group	Value	95% CI
Placebo (GT 1a, Cohort 1)	0
Voxilaprevir 50 mg (GT 1a, Cohort 1)	0
Voxilaprevir 100 mg (GT 1a, Cohort 1)	1
Voxilaprevir 300 mg (GT 1a, Cohort 1)	1
Placebo (GT 3, Cohort 2)	0
Voxilaprevir 50 mg (GT 3, Cohort 2)	0
Voxilaprevir 100 mg (GT 3, Cohort 2)	0
Voxilaprevir 300 mg (GT 3, Cohort 2)	0
Placebo (GT 2, Cohort 3)	0
Voxilaprevir 100 mg (GT 2, Cohort 3)	0
Voxilaprevir 100 mg (GT 4, Cohort 4)	0
Voxilaprevir 100 mg (GT 1b, Cohort 5)	0

Day 5 < LLOQ detected

Group	Value	95% CI
Placebo (GT 1a, Cohort 1)	0
Voxilaprevir 50 mg (GT 1a, Cohort 1)	0
Voxilaprevir 100 mg (GT 1a, Cohort 1)	0
Voxilaprevir 300 mg (GT 1a, Cohort 1)	1
Placebo (GT 3, Cohort 2)	0
Voxilaprevir 50 mg (GT 3, Cohort 2)	0
Voxilaprevir 100 mg (GT 3, Cohort 2)	0
Voxilaprevir 300 mg (GT 3, Cohort 2)	1
Placebo (GT 2, Cohort 3)	0
Voxilaprevir 100 mg (GT 2, Cohort 3)	0
Voxilaprevir 100 mg (GT 4, Cohort 4)	0
Voxilaprevir 100 mg (GT 1b, Cohort 5)	0

Day 6 < LLOQ TND

Group	Value	95% CI
Placebo (GT 1a, Cohort 1)	0
Voxilaprevir 50 mg (GT 1a, Cohort 1)	0
Voxilaprevir 100 mg (GT 1a, Cohort 1)	0
Voxilaprevir 300 mg (GT 1a, Cohort 1)	1
Placebo (GT 3, Cohort 2)	0
Voxilaprevir 50 mg (GT 3, Cohort 2)	0
Voxilaprevir 100 mg (GT 3, Cohort 2)	0
Voxilaprevir 300 mg (GT 3, Cohort 2)	0
Placebo (GT 2, Cohort 3)	0
Voxilaprevir 100 mg (GT 2, Cohort 3)	0
Voxilaprevir 100 mg (GT 4, Cohort 4)	0
Voxilaprevir 100 mg (GT 1b, Cohort 5)	0

Day 7 < LLOQ detected

Group	Value	95% CI
Placebo (GT 1a, Cohort 1)	0
Voxilaprevir 50 mg (GT 1a, Cohort 1)	0
Voxilaprevir 100 mg (GT 1a, Cohort 1)	0
Voxilaprevir 300 mg (GT 1a, Cohort 1)	0
Placebo (GT 3, Cohort 2)	0
Voxilaprevir 50 mg (GT 3, Cohort 2)	0
Voxilaprevir 100 mg (GT 3, Cohort 2)	0
Voxilaprevir 300 mg (GT 3, Cohort 2)	0
Placebo (GT 2, Cohort 3)	0
Voxilaprevir 100 mg (GT 2, Cohort 3)	0
Voxilaprevir 100 mg (GT 4, Cohort 4)	0
Voxilaprevir 100 mg (GT 1b, Cohort 5)	1

Day 8 < LLOQ detected

Group	Value	95% CI
Placebo (GT 1a, Cohort 1)	0
Voxilaprevir 50 mg (GT 1a, Cohort 1)	0
Voxilaprevir 100 mg (GT 1a, Cohort 1)	0
Voxilaprevir 300 mg (GT 1a, Cohort 1)	0
Placebo (GT 3, Cohort 2)	0
Voxilaprevir 50 mg (GT 3, Cohort 2)	0
Voxilaprevir 100 mg (GT 3, Cohort 2)	0
Voxilaprevir 300 mg (GT 3, Cohort 2)	0
Placebo (GT 2, Cohort 3)	0
Voxilaprevir 100 mg (GT 2, Cohort 3)	0
Voxilaprevir 100 mg (GT 4, Cohort 4)	0
Voxilaprevir 100 mg (GT 1b, Cohort 5)	1

Day 10 < LLOQ TND

Group	Value	95% CI
Placebo (GT 1a, Cohort 1)	0
Voxilaprevir 50 mg (GT 1a, Cohort 1)	0
Voxilaprevir 100 mg (GT 1a, Cohort 1)	0
Voxilaprevir 300 mg (GT 1a, Cohort 1)	0
Placebo (GT 3, Cohort 2)	0
Voxilaprevir 50 mg (GT 3, Cohort 2)	0
Voxilaprevir 100 mg (GT 3, Cohort 2)	0
Voxilaprevir 300 mg (GT 3, Cohort 2)	0
Placebo (GT 2, Cohort 3)	0
Voxilaprevir 100 mg (GT 2, Cohort 3)	0
Voxilaprevir 100 mg (GT 4, Cohort 4)	0
Voxilaprevir 100 mg (GT 1b, Cohort 5)	1

Week 48 < LLOQ TND

Group	Value	95% CI
Placebo (GT 1a, Cohort 1)	0
Voxilaprevir 50 mg (GT 1a, Cohort 1)	0
Voxilaprevir 100 mg (GT 1a, Cohort 1)	1
Voxilaprevir 300 mg (GT 1a, Cohort 1)	1
Placebo (GT 3, Cohort 2)	0
Voxilaprevir 50 mg (GT 3, Cohort 2)	0
Voxilaprevir 100 mg (GT 3, Cohort 2)	0
Voxilaprevir 300 mg (GT 3, Cohort 2)	0
Placebo (GT 2, Cohort 3)	0
Voxilaprevir 100 mg (GT 2, Cohort 3)	0
Voxilaprevir 100 mg (GT 4, Cohort 4)	0
Voxilaprevir 100 mg (GT 1b, Cohort 5)	0

Adverse events — posted to ClinicalTrials.gov

Time frame: Adverse Events: First dose date up to Day 3 plus 30 days; All-Cause Mortality: First dose date up to Week 48. Reporting threshold: 5%. Adverse-event reports describe events observed during the trial — not all are caused by the drug.

Placebo

Serious: 0/8 (0%)

Deaths: 0/8

Voxilaprevir 50 mg

Serious: 0/14 (0%)

Deaths: 0/14

Voxilaprevir 100 mg

Serious: 0/30 (0%)

Deaths: 0/30

Voxilaprevir 300 mg

Serious: 0/15 (0%)

Deaths: 0/15

Voxilaprevir 100 mg Fed

Serious: 1/6 (17%)

Deaths: 0/6

Voxilaprevir 100 mg + SOF/VEL 400/100 mg

Serious: 0/16 (0%)

Deaths: 0/16

Serious adverse events (1 terms)

Reaction	System	Placebo	Voxilaprevir 50 mg	Voxilaprevir 100 mg	Voxilaprevir 300 mg	Voxilaprevir 100 mg Fed	Voxilaprevir 100 mg + SOF/…
Atrial fibrillation	Cardiac disorders	—	—	—	—	—	—

Other adverse events (8 terms — click to expand)

Reaction	System	Placebo	Voxilaprevir 50 mg	Voxilaprevir 100 mg	Voxilaprevir 300 mg	Voxilaprevir 100 mg Fed	Voxilaprevir 100 mg + SOF/…
Diarrhoea	Gastrointestinal disorders	—	—	—	—	—	—
Headache	Nervous system disorders	—	—	—	—	—	—
Constipation	Gastrointestinal disorders	—	—	—	—	—	—
Contusion	Injury, poisoning and procedural complications	—	—	—	—	—	—
Arthralgia	Musculoskeletal and connective tissue disorders	—	—	—	—	—	—
Pain in extremity	Musculoskeletal and connective tissue disorders	—	—	—	—	—	—
Dizziness	Nervous system disorders	—	—	—	—	—	—
Dermatitis contact	Skin and subcutaneous tissue disorders	—	—	—	—	—	—

Most-reported serious reactions: Atrial fibrillation.

Data from ClinicalTrials.gov NCT02185794 adverse events section.

Sponsor's own description

The primary objective of the study is to evaluate the safety and tolerability of voxilaprevir (formerly GS-9857) alone or with sofosbuvir (SOF)/velpatasvir (VEL) fixed dose combination (FDC) and antiviral activity of voxilaprevir in adults with genotype 1, 2, 3, 4 hepatitis C virus (HCV) infection. All participants will be monitored for up to 48 weeks after the last dose.

Publications & conference data

5 peer-reviewed publications reference this trial (live from Europe PMC):

Direct-acting antivirals for chronic hepatitis C.
Jakobsen JC, Nielsen EE, Feinberg J, Katakam KK, et al · · 2017 · cited 61× · PMID 28922704 · DOI 10.1002/14651858.cd012143.pub3
Pharmacokinetics, Efficacy, and Safety of Hepatitis C Virus Drugs in Patients with Liver and/or Renal Impairment.
Smolders EJ, de Kanter CT, van Hoek B, Arends JE, et al · · 2016 · cited 57× · PMID 27098247 · DOI 10.1007/s40264-016-0420-2
Direct-acting antivirals for chronic hepatitis C.
Jakobsen JC, Nielsen EE, Feinberg J, Katakam KK, et al · · 2017 · cited 37× · PMID 28585310 · DOI 10.1002/14651858.cd012143.pub2
Characterization of HCV resistance from a 3-day monotherapy study of voxilaprevir, a novel pangenotypic NS3/4A protease inhibitor.
Lawitz E, Yang JC, Stamm LM, Taylor JG, et al · · 2018 · cited 23× · PMID 29063860 · DOI 10.3851/imp3202
Sofosbuvir + velpatasvir + voxilaprevir for the treatment of hepatitis C infection.
Cory TJ, Mu Y, Gong Y, Kodidela S, et al · · 2018 · cited 9× · PMID 29634360 · DOI 10.1080/14656566.2018.1459567

Verify or expand the search:

Other trials of Voxilaprevir

Trials testing the same drug.

NCT05717400 — Improving Response to Immunotherapy in Patients With Advanced Hepatocellular Carcinoma and Chronic Hepatitis C Virus Inf · Phase 4 · terminated
NCT02402452 — Pharmacokinetics of Voxilaprevir in Adults With Normal Renal Function and Severe Renal Impairment · Phase 1 · completed
NCT02397707 — Pharmacokinetics of Voxilaprevir in Adults With Normal Hepatic Function and Moderate or Severe Hepatic Impairment · Phase 1 · completed

Other recruiting trials for Hepatitis C Virus Infection

Currently open trials in the same condition.

NCT06870019 — Hepatitis C Tracker Study · NA · recruiting
NCT06463912 — Screening for Hepatitis c in People Who Inject Drugs in Armenia-Colombia · recruiting
NCT06718530 — Characterization of Immune Genotypes and Antibody Profiles to Foster the discoVERY of diagnosticbioMARKERS of Liver Canc · recruiting
NCT06155006 — Adult Screening for Hepatitis c and Linkage to Treatment in Hospitals in Colombia · recruiting
NCT06431945 — Early Detection of HCV in Injection Drug Users · recruiting

Other Gilead Sciences trials

Trials by the same sponsor.

NCT07115368 — Study of GS-1219 in Participants With HIV-1 · Phase 1 · terminated
NCT06784973 — Study of Obeldesivir to Treat Children With Respiratory Syncytial Virus (RSV) Infection · Phase 2 · terminated
NCT06683482 — A Qualitative Study on Advanced Breast Cancer Patients and Their Caregivers in Spain · completed
NCT06613685 — Study of Oral Weekly GS-1720 and GS-4182 Compared With Biktarvy in People With HIV-1 Who Have Not Been Treated · Phase 2, PHASE3 · terminated
NCT06585150 — Study of Obeldesivir to Treat Nonhospitalized Adults With Acute Respiratory Syncytial Virus (RSV) Infection · Phase 2 · terminated

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02185794 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Gilead Sciences
Last refreshed: 17 September 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02185794.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing